Literature DB >> 17850234

Late onset of development of natural anti-nonGal antibodies in infant humans and baboons: implications for xenotransplantation in infants.

Pleunie P M Rood1, Hao-Chih Tai, Hidetaka Hara, Cassandra Long, Mohamed Ezzelarab, Yih J Lin, Dirk J van der Windt, Jamie Busch, David Ayares, Jan N M Ijzermans, Roman F Wolf, Rizwan Manji, Leonard Bailey, David K C Cooper.   

Abstract

If an ABO-incompatible heart is transplanted into an infant before natural antibodies have developed to the specific donor carbohydrate A/B antigen(s), then B-cell tolerance to the donor A/B antigen is achieved, and these antibodies never develop. Anti-carbohydrate antibodies play a role in the rejection of wild type (WT) and alpha1,3-galactosyltransferase gene-knockout (GT-KO) pig xenografts. We investigated development of these antibodies in infant baboons and humans. Serum samples from infant baboons (n = 42) and humans (n = 42) were tested by flow cytometry for immunoglobulin M and immunoglobulin G binding to peripheral blood mononuclear cells from WT and GT-KO pigs, and for complement-dependent cytotoxicity. The presence of anti-blood group antibodies was tested in baboon serum. In infant baboons and humans, cytotoxic anti-Galalpha1,3Gal antibodies develop during the first 3 months, and steadily increase with age, whereas cytotoxic anti-nonGal antibodies are either absent or minimal in the majority of cases throughout the first year of life. Anti-blood group antibodies were not detected before 16 weeks of age. Our data suggest GT-KO pig organ/cell transplants could be carried out in early infancy in the absence of preformed cytotoxic anti-nonGalalpha1,3Gal antibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850234     DOI: 10.1111/j.1432-2277.2007.00546.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  20 in total

1.  Is there a correlation between anti-pig antibody levels in humans and geographic location during childhood?

Authors:  Goutham Kumar; Vikas Satyananda; Jason Fang; Hao Zhou; Minoru Fujita; Burcin Ekser; Cassandra Long; Eefje Dons; Qing Sun; David Ayares; Hidetaka Hara; David K C Cooper
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

2.  T-cell-based immunosuppressive therapy inhibits the development of natural antibodies in infant baboons.

Authors:  Eefje M Dons; Claudia Montoya; Cassandra E Long; Hidetaka Hara; Gabriel J Echeverri; Burcin Ekser; Corin Ezzelarab; Dasha Roa Medellin; Dirk J van der Windt; Noriko Murase; Lora H Rigatti; Robert Wagner; Roman F Wolf; Mohamed Ezzelarab; Lori J West; Jan N M Ijzermans; David K C Cooper
Journal:  Transplantation       Date:  2012-04-27       Impact factor: 4.939

Review 3.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

4.  Complete absence of the αGal xenoantigen and isoglobotrihexosylceramide in α1,3galactosyltransferase knock-out pigs.

Authors:  Gisella L Puga Yung; Yunsen Li; Lubor Borsig; Anne-Laure Millard; Maria B Karpova; Dapeng Zhou; Jörg D Seebach
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

5.  Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs.

Authors:  Whayoung Lee; Hidetaka Hara; Mohamed B Ezzelarab; Hayato Iwase; Rita Bottino; Cassandra Long; Jagdeece Ramsoondar; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2016-03-14       Impact factor: 3.907

6.  Anti-gal antibodies in α1,3-galactosyltransferase gene-knockout pigs.

Authors:  Jason Fang; Anneke Walters; Hidetaka Hara; Cassandra Long; Peter Yeh; David Ayares; David K C Cooper; John Bianchi
Journal:  Xenotransplantation       Date:  2012-09-13       Impact factor: 3.907

7.  Collagenous colitis-like condition in immunosuppressed infant baboons.

Authors:  Eefje M Dons; Gabriel J Echeverri; Lora H Rigatti; Edwin Klein; Claudia Montoya; Roman F Wolf; Jan N M Ijzermans; David K C Cooper; Robert Wagner
Journal:  Inflamm Bowel Dis       Date:  2012-01-31       Impact factor: 5.325

Review 8.  Immunobiological barriers to xenotransplantation.

Authors:  David K C Cooper; Burcin Ekser; A Joseph Tector
Journal:  Int J Surg       Date:  2015-07-06       Impact factor: 6.071

9.  Are there advantages in the use of specific pathogen-free baboons in pig organ xenotransplantation models?

Authors:  Huidong Zhou; Hayato Iwase; Roman F Wolf; Burcin Ekser; Mohamed Ezzelarab; Hidetaka Hara; Gary White; David K C Cooper
Journal:  Xenotransplantation       Date:  2014-02-18       Impact factor: 3.907

10.  Frankenswine, or bringing home the bacon: How close are we to clinical trials in xenotransplantation?

Authors:  David Kc Cooper
Journal:  Organogenesis       Date:  2008-01       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.